Home » Topics » Infection, BioWorld Science

Infection, BioWorld Science
RSS

Enrollment ongoing in phase II/III study of pyronaridine/artesunate for the treatment of COVID-19

April 9, 2021

NIH initiates study to assess allergic reactions to Moderna and Pfizer-BioNTech COVID-19 vaccines

April 8, 2021

Enrollment ongoing in phase II study of IC-14 chimeric antibody in patients with COVID-19

April 8, 2021

Shionogi and Hsiri Therapeutics patent compounds for mycobacterial infections

April 8, 2021

AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection

April 7, 2021

Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors

April 7, 2021

MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones

April 7, 2021

Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I

April 7, 2021

First patient dosed in a phase II study of ensovibep for the treatment of COVID-19

April 7, 2021

Zydus reports positive phase III data for PegiHep in patients with COVID-19

April 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...